OBJECTIVE: To quantify by meta-analysis the genetic effect of the HLA-B5 or HLA-B51 (HLA-B51/B5) allele on the risk of developing Behçet's disease (BD) and to look for potential effect modifiers. METHODS: Relevant studies were identified using the PubMed Medline database and manual searches of the literature. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated by using the random-effects model. Subgroup meta-analyses and meta-regression analyses were undertaken to investigate the effects of selected study-level parameters on the pooled OR. Heterogeneity was assessed using the I2 statistic. Pooled results were used to calculate population-attributable risks (PAR) for BD in relationship to HLA-B51/B5. RESULTS: A total of 4,800 patients with BD and 16,289 controls from 78 independent studies (published 1975-2007) were selected. The pooled OR of HLA-B51/B5 allele carriers to develop BD compared with noncarriers was 5.78 (95% CI 5.00-6.67), with moderate between-study heterogeneity (I2 = 61%). The subgroup analyses stratifying studies by geographic locations (Eastern Asia, Middle East/North Africa, Southern Europe, Northern/Eastern Europe) yielded consistent OR ranges (5.31-7.20), with I2 ranges of 52-70%. Univariate random-effects meta-regression indicated the percentage of male BD cases (P = 0.008) as a source of heterogeneity. The PAR within the various geographic areas were estimated at 32-52%. CONCLUSION: The strength of the association between BD and HLA-B51/B5, and its consistency across populations of various ethnicities, lends further support to this allele being a primary and causal risk determinant for BD. Variations according to sex support an interaction of this allele with BD characteristics.
OBJECTIVE: To quantify by meta-analysis the genetic effect of the HLA-B5 or HLA-B51 (HLA-B51/B5) allele on the risk of developing Behçet's disease (BD) and to look for potential effect modifiers. METHODS: Relevant studies were identified using the PubMed Medline database and manual searches of the literature. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated by using the random-effects model. Subgroup meta-analyses and meta-regression analyses were undertaken to investigate the effects of selected study-level parameters on the pooled OR. Heterogeneity was assessed using the I2 statistic. Pooled results were used to calculate population-attributable risks (PAR) for BD in relationship to HLA-B51/B5. RESULTS: A total of 4,800 patients with BD and 16,289 controls from 78 independent studies (published 1975-2007) were selected. The pooled OR of HLA-B51/B5 allele carriers to develop BD compared with noncarriers was 5.78 (95% CI 5.00-6.67), with moderate between-study heterogeneity (I2 = 61%). The subgroup analyses stratifying studies by geographic locations (Eastern Asia, Middle East/North Africa, Southern Europe, Northern/Eastern Europe) yielded consistent OR ranges (5.31-7.20), with I2 ranges of 52-70%. Univariate random-effects meta-regression indicated the percentage of male BD cases (P = 0.008) as a source of heterogeneity. The PAR within the various geographic areas were estimated at 32-52%. CONCLUSION: The strength of the association between BD and HLA-B51/B5, and its consistency across populations of various ethnicities, lends further support to this allele being a primary and causal risk determinant for BD. Variations according to sex support an interaction of this allele with BD characteristics.
Authors: John P A Ioannidis; Thomas A Trikalinos; Evangelia E Ntzani; Despina G Contopoulos-Ioannidis Journal: Lancet Date: 2003-02-15 Impact factor: 79.321
Authors: P Picco; B Porfirio; M Gattorno; A Buoncompagni; F Falcini; R Cusano; D Bordo; V Pistoia; R Ravazzolo; M Seri Journal: Int J Mol Med Date: 2002-11 Impact factor: 4.101
Authors: V Pittoni; S Vaglio; L Magrini; M Accorinti; P Pivetti-Pezzi; G Girelli; G Valesini Journal: Rheumatol Int Date: 2003-01-18 Impact factor: 2.631
Authors: A Gül; F A Uyar; M Inanç; L Ocal; J H Barrett; O Aral; M Koniçe; G Saruhan-Direskeneli Journal: Genes Immun Date: 2002-09 Impact factor: 2.676
Authors: Pablo Guasp; Elena Lorente; Adrian Martín-Esteban; Eilon Barnea; Paolo Romania; Doriana Fruci; JonasJ W Kuiper; Arie Admon; José A López de Castro Journal: Mol Cell Proteomics Date: 2019-05-15 Impact factor: 5.911
Authors: Elaine F Remmers; Fulya Cosan; Yohei Kirino; Michael J Ombrello; Neslihan Abaci; Colleen Satorius; Julie M Le; Barbara Yang; Benjamin D Korman; Aris Cakiris; Oznur Aglar; Zeliha Emrence; Hulya Azakli; Duran Ustek; Ilknur Tugal-Tutkun; Gulsen Akman-Demir; Wei Chen; Christopher I Amos; Michael B Dizon; Afet Akdag Kose; Gulsevim Azizlerli; Burak Erer; Oliver J Brand; Virginia G Kaklamani; Phaedon Kaklamanis; Eldad Ben-Chetrit; Miles Stanford; Farida Fortune; Marwen Ghabra; William E R Ollier; Young-Hun Cho; Dongsik Bang; John O'Shea; Graham R Wallace; Massimo Gadina; Daniel L Kastner; Ahmet Gül Journal: Nat Genet Date: 2010-07-11 Impact factor: 38.330